Risk factors for clinical coronary heart disease in systemic lupus erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) study

Journal of Rheumatology

Volumn 37, Issue 2, 2010, Pages 322-329

  Haque, Sahena ^a,b   Gordon, Caroline ^c   Isenberg, David ^d   Rahman, Anisur ^d   Lanyon, Peter ^e   Bell, Aubrey ^f   Emery, Paul ^g   McHugh, Neil ^h   Teh, Lee Suan ⁱ   Scott, David G I ^j   Akil, Mohamed ^k   Naz, Sophia ^k   Andrews, Jacqueline ^l   Griffiths, Bridget ^m   Harris, Helen ⁿ   Youssef, Hazem ^o   McLaren, John ⁿ   Toescu, Veronica ^p   Devakumar, Vinodh ⁱ   Teir, Jamal ^q   Bruce, Ian N ^a   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^g CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^h ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

ⁱ ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^j NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^k ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^l NORTHWICK PARK HOSPITAL   (United Kingdom)

^m FREEMAN HOSPITAL   (United Kingdom)

ⁿ Cameron Hospital   (United States)

^o ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^p Queen Elizabeth Hospital

^q SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

more..

Author keywords

Coronary heart disease; Disease activity; Risk factors; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; LUPUS ANTICOAGULANT; METHOTREXATE; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; FEMALE; HEART INFARCTION; HUMAN; LUPUS AND ATHEROSCLEROSIS EVALUATION OF RISK; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 76649142028     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090306     Document Type: Article

References (35)

1. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
2. Bruce IN, Urowitz MB, Gladman DD, Ibanez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159-67.
3. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine Baltimore 1992;71:291-302.
4. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331-7.
5. Freire BF, da Silva RC, Fabro AT, dos Santos DC. Is systemic lupus erithematosus a new risk factor for atherosclerosis? Arq Bras Cardiol 2006;87:300-6.
6. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987;14 Suppl 13:223-6.
7. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
8. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U, et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 2001;104:1887-93.
9. Urowitz MB, Ibanez D, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007;34:70-5.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
11. Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. Am Heart J 1984;108:150-8.
12. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
13. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
14. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
15. Johnson AE, Gordon C, Palmer RG, Bacon PA. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995;38:551-8.
16. Bessant R, Duncan R, Ambler G, Swanton J, Isenberg DA, Gordon C, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum 2006;55:892-9.
17. Ho KT, Ahn CW, Alarcon GS, Baethge BA, Tan FK, Roseman J, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology 2005;44:1303-7.
18. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:1583-633.
19. Kitagawa Y, Gotoh F, Koto A, Okayasu H. Stroke in systemic lupus erythematosus. Stroke 1990;21:1533-9.
20. Futrell N, Millikan C. Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 1989;20:583-91.
21. Chi YW, Jaff MR. Optimal risk factor modification and medical management of the patient with peripheral arterial disease. Catheter Cardiovasc Interv 2008;71:475-89.
22. Bruce IN, Urowitz MB, Gladman DD, Hallett DC. Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999;26:2137-43.
23. Urowitz MB, Gladman DD, Ibanez D, Berliner Y. Modification of hypertension and hypercholesterolaemia in patients with systemic lupus erythematosus: a quality improvement study. Ann Rheum Dis 2006;65:115-7.
24. Costenbader KH, Liang MH, Chibnik LB, Aizer J, Kwon H, Gall V, et al. A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 2007;27:1071-7.
25. Maddison P, Farewell V, Isenberg D, Aranow C, Bae SC, Barr S, et al. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol 2002;29:913-7.
26. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-95.
27. Ahmad Y, Shelmerdine J, Bodill H, Lunt M, Pattrick MG, Teh LS, et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology 2007;46:983-8.
28. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003;62:1071-7.
29. Karp I, Abrahamowicz M, Fortin PR, Pilote L, Neville C, Pineau CA, et al. Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008;59:169-75.
30. Nicolo D, Goldman BI, Monestier M. Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum 2003;48:2974-8.
31. Bossert T, Falk V, Gummert JF, Rahmel A, Mohr FW. Coronary artery bypass grafting in patients with systemic lupus erythematosus. Z Kardiol 2003;92:219-21.
32. Bozbuga N, Erentug V, Kaya E, Akinci E, Yakut C. Coronary artery bypass grafting in patients with systemic lupus erythematosus. J Card Surg 2004;19:471-2.
33. Ward MM. Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. Arthritis Rheum 2004;50:3170-6.
34. Vila LM, Alarcon GS, McGwin G Jr, Friedman AW, Baethge BA, Bastian HM, et al. Early clinical manifestations, disease activity and damage of systemic lupus erythematosus among two distinct US Hispanic subpopulations. Rheumatology 2004;43:358-63.
35. Bruce IN. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 2005;44:1492-502.